Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 24;11(7):944.
doi: 10.3390/healthcare11070944.

Clinical Characterization and Outcomes of Patients with Hypercreatinemia Affected by COVID-19

Ahmed M E Elkhalifa  1   2 , Naveed Nazir Shah  3 , Zaid Khan  3 , Sofi Imtiyaz Ali  4 , Showkat Ul Nabi  5 , Showkeen Muzamil Bashir  4 , Masood Saleem Mir  6 , Elsharif A Bazie  7 , Abozer Y Elderdery  8 , Awadh Alanazi  8 , Fawaz O Alenazy  8 , Elsadig Mohamed Ahmed  9   10
Affiliations

Clinical Characterization and Outcomes of Patients with Hypercreatinemia Affected by COVID-19

Ahmed M E Elkhalifa et al. Healthcare (Basel). .

Abstract

The present study evaluated the clinical presentation and outcome of COVID-19 patients with underlying hypercreatinemia at the time of hospitalization. A retrospective observational study was conducted from the 23rd of March 2020 to the 15th of April 2021 in 1668 patients confirmed positive for COVID-19 in the Chest Disease Hospital in Srinagar, India. The results of the present study revealed that out of 1668 patients, 339 with hypercreatinemia had significantly higher rates of admission to the intensive care unit (ICU), severe manifestations of the disease, need for mechanical ventilation, and all-cause mortality. Multivariable analysis revealed that age, elevated creatinine concentrations, IL-1, D-Dimer, and Hs-Crp were independent risk factors for in-hospital mortality. After adjusted analysis, the association of creatinine levels remained strongly predictive of all-cause, in-hospital mortality (HR-5.34; CI-4.89-8.17; p ≤ 0.001). The amelioration of kidney function may be an effective method for achieving creatinemic targets and, henceforth, might be beneficial for improving outcomes in patients with COVID-19.

Keywords: COVID-19; hypercreatinemic; intensive care; mechanical ventilation; outcome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
SpO2 levels at admission (hospitalization) in patients with normocreatinemia (Group-I) and hypercreatinemia (Group-2).
Figure 2
Figure 2
Ferritin levels at admission (hospitalization) in patients with normocreatinemia (Group-1) and hypercreatinemia (Group-2).
Figure 3
Figure 3
Procalcitonin levels at admission (hospitalization) in patients with normocreatinemia (Group-I) and hypercreatinemia (Group-2).
Figure 4
Figure 4
Hs-CRP levels at admission (hospitalization) in patients with normocreatinemia (Group-I) and hypercreatinemia (Group-2).
Figure 5
Figure 5
Interluekin-2 levels at admission (hospitalization) in patients with normocreatinemia (Group-I) and hypercreatinemia (Group-2).
Figure 6
Figure 6
Regression analysis between admission creatinine levels and admission Hs-CRP, ferritin, IL-2 and IL-6 levels.
Figure 7
Figure 7
Hospitalization (days) in patients with normocreatinemia (Group-I) and hypercreatinemia (Group-2).
Figure 8
Figure 8
Risk-adjusted Cox regression analysis curves through 25 days for patients with COVID-19 stratified by normocreatinemia (Group-I) and hypercreatinemia (Group-2).
See this image and copyright information in PMC

References

    1. Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X., Liu L., Shan H., Lei C.-L., Hui D.S., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Elkhalifa A.M., Nabi S.U., Shah N.N., Dar K.A., Quibtiya S., Bashir S.M., Ali S.I., Taifa S., Hussain I. Evaluation of Convalescent Plasma in the Management of Critically Ill COVID-19 Patients (with No Detectable Neutralizing Antibodies Nab) in Kashmir, India. Healthcare. 2023;11:317. doi: 10.3390/healthcare11030317. - DOI - PMC - PubMed
    1. Shah N.N., Nabi S.U., Rather M.A., Kalwar Q., Ali S.I., Sheikh W.M., Ganai A., Bashir S.M. An update on emerging therapeutics to combat COVID-19. Basic Clin. Pharmacol. Toxicol. 2021;129:104–129. - PMC - PubMed
    1. Luo X., Estill J., Wang Q., Lv M., Liu Y., Liu E., Chen Y. The psychological impact of quarantine on coronavirus disease 2019 (COVID-19) Psychiatry Res. 2020;291:113193. - PMC - PubMed
    1. Huang I., Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): Systematic review and meta-analysis. J. Intensive Care. 2020;8:1–10. - PMC - PubMed